Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 1
2015 7
2017 2
2018 2
2019 1
2020 2
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean mansson r (92 results)?
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.
Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED Jr, Ngan Y, Petersen LK, Lazcano-Ponce E, Pitisuttithum P, Restrepo JA, Stuart G, Woelber L, Yang YC, Cuzick J, Garland SM, Huh W, Kjaer SK, Bautista OM, Chan IS, Chen J, Gesser R, Moeller E, Ritter M, Vuocolo S, Luxembourg A; Broad Spectrum HPV Vaccine Study. Joura EA, et al. N Engl J Med. 2015 Feb 19;372(8):711-23. doi: 10.1056/NEJMoa1405044. N Engl J Med. 2015. PMID: 25693011 Free article. Clinical Trial.
Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
Peterson J, Drazan D, Czajka H, Maguire J, Pregaldien JL, Seppa I, Maansson R, O'Neill R, Balmer P, Jodar L, Jansen KU, Anderson AS, Perez JL, Beeslaar J. Peterson J, et al. Among authors: maansson r. Lancet Infect Dis. 2023 Dec;23(12):1370-1382. doi: 10.1016/S1473-3099(23)00191-3. Epub 2023 Aug 11. Lancet Infect Dis. 2023. PMID: 37579773 Clinical Trial.
A phase 3 study to assess the immunogenicity, safety, and tolerability of MenB-FHbp administered as a 2-dose schedule in adolescents and young adults.
Drazan D, Czajka H, Maguire JD, Pregaldien JL, Maansson R, O'Neill R, Anderson AS, Balmer P, Beeslaar J, Perez JL. Drazan D, et al. Among authors: maansson r. Vaccine. 2022 Jan 21;40(2):351-358. doi: 10.1016/j.vaccine.2021.11.053. Epub 2021 Dec 24. Vaccine. 2022. PMID: 34961633 Free article. Clinical Trial.
Immunogenicity and Safety of a 9-Valent HPV Vaccine.
Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, Huang LM, Kim DS, Pitisuttithum P, Chen J, Christiano S, Maansson R, Moeller E, Sun X, Vuocolo S, Luxembourg A. Van Damme P, et al. Among authors: maansson r. Pediatrics. 2015 Jul;136(1):e28-39. doi: 10.1542/peds.2014-3745. Pediatrics. 2015. PMID: 26101366 Clinical Trial.
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward BJ, Senders S, Eiden JJ, Jansen KU, Anderson AS, York LJ, Jones TR, Harris SL, O'Neill R, Radley D, Maansson R, Prégaldien JL, Ginis J, Staerke NB, Perez JL; B1971009 and B1971016 Trial Investigators. Ostergaard L, et al. Among authors: maansson r. N Engl J Med. 2017 Dec 14;377(24):2349-2362. doi: 10.1056/NEJMoa1614474. N Engl J Med. 2017. PMID: 29236639 Free article. Clinical Trial.
Immunogenicity and safety of the 9-valent HPV vaccine in men.
Castellsagué X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, Group T, Shields C, Liu K, Maansson R, Luxembourg A, Kaplan SS. Castellsagué X, et al. Among authors: maansson r. Vaccine. 2015 Nov 27;33(48):6892-901. doi: 10.1016/j.vaccine.2015.06.088. Epub 2015 Jul 2. Vaccine. 2015. PMID: 26144901
Modeling excess zeroes in an integrated analysis of vaccine safety.
Maansson R, Radley D, Jiang Q, Beeslaar J, Patterson S, Absalon J, Perez J. Maansson R, et al. Hum Vaccin Immunother. 2018 Jun 3;14(6):1530-1533. doi: 10.1080/21645515.2018.1433972. Epub 2018 Feb 23. Hum Vaccin Immunother. 2018. PMID: 29393713 Free PMC article.
Persistence of hSBA titers elicited by the meningococcal serogroup B vaccine menB-FHbp for up to 4 years after a 2- or 3-dose primary series and immunogenicity, safety, and tolerability of a booster dose through 26 months.
Østergaard L, Vesikari T, Senders SD, Flodmark CE, Kosina P, Jiang HQ, Maguire JD, Absalon J, Jansen KU, Harris SL, Maansson R, Balmer P, Beeslaar J, Perez JL. Østergaard L, et al. Among authors: maansson r. Vaccine. 2021 Jul 22;39(32):4545-4554. doi: 10.1016/j.vaccine.2021.06.005. Epub 2021 Jun 30. Vaccine. 2021. PMID: 34215452 Clinical Trial.
22 results